Sadayuki Kawai1, Tadakazu Shimoda2, Takashi Nakajima2, Masanori Terashima3, Katsuhiro Omae4, Nozomu Machida5, Hirofumi Yasui1. 1. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun 411-8777, Shizuoka, Japan. 2. Division of Pathology, Shizuoka Cancer Center, Sunto-gun 411-8777, Shizuoka, Japan. 3. Division of Gastric Surgery, Shizuoka Cancer Center, Nagaizumi 411-0932, Shizuoka, Japan. 4. Clinical Research Center, Shizuoka Cancer Center, Sunto-gun 411-8777, Shizuoka, Japan. 5. Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun 411-8777, Shizuoka, Japan.
Abstract
BACKGROUND: Although pathological response is a common endpoint used to assess the efficacy of neoadjuvant chemotherapy (NAC) for gastric cancer, the problem of a low rate of concordance from evaluations among pathologists remains unresolved. Moreover, there is no globally accepted consensus regarding the optimal evaluation. A previous study based on a clinical trial suggested that pathological response measured using digitally captured virtual microscopic slides predicted patients' survival well. However, the pathological concordance rate of this approach and its usefulness in clinical practice were unknown. AIM: To investigate the prognostic utility of pathological response measured using digital microscopic slides in clinical practice. METHODS: We retrospectively evaluated pathological specimens of gastric cancer patients who underwent NAC followed by surgery and achieved R0 resection between March 2009 and May 2015. Residual tumor area and primary tumor beds were measured in one captured image slide, which contained the largest diameter of the resected specimens. We classified patients with < 10% residual tumor relative to the primary tumorous area as responders, and the rest as non-responders; we then compared overall survival (OS) and relapse-free survival (RFS) between these two groups. Next, we compared the prognostic utility of this method using conventional Japanese criteria. RESULTS: Fifty-four patients were evaluated. The concordance rate between two evaluators was 96.2%. Median RFS of 25 responders and 29 non-responders was not reached (NR) vs 18.2 mo [hazard ratio (HR) = 0.35, P = 0.023], and median OS was NR vs 40.7 mo (HR = 0.3, P = 0.016), respectively. This prognostic value was statistically significant even after adjustment for age, eastern cooperative oncology group performance status, macroscopic type, reason for NAC, and T- and N-classification (HR = 0.23, P = 0.018). This result was also observed even in subgroup analyses for different macroscopic types (Borrmann type 4/non-type 4) and histological types (differentiated/undifferentiated). Moreover, the adjusted HR for OS between responders and non-responders was lower in this method than that in the conventional histological evaluation of Japanese Classification of Gastric Carcinoma criteria (0.23 vs 0.39, respectively). CONCLUSION: The measurement of pathological response using digitally captured virtual microscopic slides may be useful in clinical practice.
BACKGROUND: Although pathological response is a common endpoint used to assess the efficacy of neoadjuvant chemotherapy (NAC) for gastric cancer, the problem of a low rate of concordance from evaluations among pathologists remains unresolved. Moreover, there is no globally accepted consensus regarding the optimal evaluation. A previous study based on a clinical trial suggested that pathological response measured using digitally captured virtual microscopic slides predicted patients' survival well. However, the pathological concordance rate of this approach and its usefulness in clinical practice were unknown. AIM: To investigate the prognostic utility of pathological response measured using digital microscopic slides in clinical practice. METHODS: We retrospectively evaluated pathological specimens of gastric cancerpatients who underwent NAC followed by surgery and achieved R0 resection between March 2009 and May 2015. Residual tumor area and primary tumor beds were measured in one captured image slide, which contained the largest diameter of the resected specimens. We classified patients with < 10% residual tumor relative to the primary tumorous area as responders, and the rest as non-responders; we then compared overall survival (OS) and relapse-free survival (RFS) between these two groups. Next, we compared the prognostic utility of this method using conventional Japanese criteria. RESULTS: Fifty-four patients were evaluated. The concordance rate between two evaluators was 96.2%. Median RFS of 25 responders and 29 non-responders was not reached (NR) vs 18.2 mo [hazard ratio (HR) = 0.35, P = 0.023], and median OS was NR vs 40.7 mo (HR = 0.3, P = 0.016), respectively. This prognostic value was statistically significant even after adjustment for age, eastern cooperative oncology group performance status, macroscopic type, reason for NAC, and T- and N-classification (HR = 0.23, P = 0.018). This result was also observed even in subgroup analyses for different macroscopic types (Borrmann type 4/non-type 4) and histological types (differentiated/undifferentiated). Moreover, the adjusted HR for OS between responders and non-responders was lower in this method than that in the conventional histological evaluation of Japanese Classification of Gastric Carcinoma criteria (0.23 vs 0.39, respectively). CONCLUSION: The measurement of pathological response using digitally captured virtual microscopic slides may be useful in clinical practice.
Entities:
Keywords:
Drug therapy; Neoadjuvant therapy; Pathology; Prognostic factor; Stomach neoplasm
Authors: Karen Becker; Rupert Langer; Daniel Reim; Alexander Novotny; Christian Meyer zum Buschenfelde; Jutta Engel; Helmut Friess; Heinz Hofler Journal: Ann Surg Date: 2011-05 Impact factor: 12.969
Authors: J A Ajani; P F Mansfield; C H Crane; T T Wu; S Lunagomez; P M Lynch; N Janjan; B Feig; J Faust; J C Yao; R Nivers; J Morris; P W Pisters Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: L E Ferri; S Ades; T Alcindor; M Chasen; V Marcus; M Hickeson; G Artho; M P Thirlwell Journal: Ann Oncol Date: 2011-10-29 Impact factor: 32.976
Authors: B Brenner; M A Shah; M S Karpeh; M Gonen; M F Brennan; D G Coit; D S Klimstra; L H Tang; D P Kelsen Journal: Ann Oncol Date: 2006-06-20 Impact factor: 32.976
Authors: V Valenti; J L Hernandez-Lizoaín; M C Beorlegui; J A Diaz-Gozalez; F M Regueira; J J Rodriguez; A Viudez; I Sola; J A Cienfuegos Journal: J Surg Oncol Date: 2011-04-20 Impact factor: 3.454
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: T Yoshikawa; M Sasako; S Yamamoto; T Sano; H Imamura; K Fujitani; H Oshita; S Ito; Y Kawashima; N Fukushima Journal: Br J Surg Date: 2009-09 Impact factor: 6.939